Even in the low-dose group, however, tumor control was significantly better than monotherapy antibody treatment to PD1 (RMP1–14), PD-L1 (10F.9G2) or OX40 (OX86) and equivalent to the antibody combinations (Fig. 5a-b). This evidence concerns the gene TNFRSF4 and neoplasm.